Associated Papers
Clinical and Genetic Landscape of Glioblastoma, IDH-Wildtype With FGFR Gene Family Alterations.
Kegoya Y et al.
Cancer Science, 2026
The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1.
Shoumariyeh K et al.
Leukemia, 2026
Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.
Xiang S et al.
Journal of Medicinal Chemistry, 2026
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.
Tangermann C et al.
Nature Genetics, 2026
FGFR1 Tyrosine Kinase Domain Variant p.Val561Met in Caudal Dysraphism: A Case Report.
Goel H et al.
Birth Defects Research, 2025
Discovery and Characterization of Novel FGFR1 V561M Inhibitors via Virtual Screening and Molecular Dynamics Simulations.
Lu Y et al.
Acs Medicinal Chemistry Letters, 2025
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.
Apfelbaum AA et al.
Nature Communications, 2025
Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers.
Hoskins EL et al.
Npj Precision Oncology, 2025
Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations.
Morfouace M et al.
European Journal of Cancer (oxford, England : 1990), 2025
Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model-Based Prediction.
Ziegler M et al.
Jco Precision Oncology, 2025
Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors.
Deng W et al.
European Journal of Medicinal Chemistry, 2024
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D.
Zheng Q et al.
Nature Chemical Biology, 2024
Computational biophysical characterization of the effect of gatekeeper mutations on the binding of ponatinib to the FGFR kinase.
Mahapatra S et al.
Archives of Biochemistry and Biophysics, 2024
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
Pike KG et al.
Journal of Medicinal Chemistry, 2024
Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R.
Lin Q et al.
Communications Chemistry, 2024
Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer.
Chow F et al.
Frontiers in Immunology, 2024
Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor.
Michaelides IN et al.
Journal of Medicinal Chemistry, 2023
Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers.
Brown LM et al.
Oncogene, 2023
Pan-cancer clinical impact of latent drivers from double mutations.
Yavuz BR et al.
Communications Biology, 2023
Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.
Popiel D et al.
Frontiers in Oncology, 2023
Discovery of 2-Amino-7-sulfonyl-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Potent Reversible FGFR Inhibitors with Gatekeeper Mutation Tolerance: Design, Synthesis, and Biological Evaluation.
Xie W et al.
Journal of Medicinal Chemistry, 2022
Targeting Gatekeeper Mutations for Kinase Drug Discovery.
Zhou Y et al.
Journal of Medicinal Chemistry, 2022
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants.
Lin Q et al.
Communications Chemistry, 2022
The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer.
Choi YJ et al.
Cancer Research, 2022
Discovery of 1H-Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors.
Leśniak RK et al.
Acs Medicinal Chemistry Letters, 2022
Structural study of ponatinib in inhibiting SRC kinase.
Guo M et al.
Biochemical and Biophysical Research Communications, 2022
Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer.
Thomas J et al.
Cancers, 2022
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.
Zengin ZB et al.
Urologic Oncology, 2022
Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer.
Moes-Sosnowska J et al.
Frontiers in Oncology, 2022
Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
Kawahata W et al.
Journal of Medicinal Chemistry, 2021
Intrinsic relative preference profile of pan-kinase inhibitor drug staurosporine towards the clinically occurring gatekeeper mutations in Protein Tyrosine Kinases.
Ren Z et al.
Computational Biology and Chemistry, 2021
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.
Portelinha A et al.
Cell Reports. Medicine, 2021
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
Krook MA et al.
British Journal of Cancer, 2021
Dual activating FGFR1 mutations in pediatric pilomyxoid astrocytoma.
Fomchenko EI et al.
Molecular Genetics & Genomic Medicine, 2021
Structural Basis for Targeting the Folded P-Loop Conformation of c-MET.
Collie GW et al.
Acs Medicinal Chemistry Letters, 2021
Mutational drivers of cancer cell migration and invasion.
Novikov NM et al.
British Journal of Cancer, 2021
Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice.
Čerina D et al.
Pathology Oncology Research : Por, 2021
A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of binding.
Pflug A et al.
The Biochemical Journal, 2020
Therapeutics potentiating microglial p21-Nrf2 axis can rescue neurodegeneration caused by neuroinflammation.
Nakano-Kobayashi A et al.
Science Advances, 2020